We next decided to implement our parallel pyrosequencing protocol and sequence analysis approach to screen for mutations in the BRCA1 and BRCA2 genes in a series of 101 patients with breast and ovarian cancer. This evidence concerns the gene BRCA1 and ovarian carcinoma.